Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy [PDF]
, 2013 To investigate the effect of phosphodiesterase type 5 inhibitor on urinary continence recovery after bilateral nerve-sparing radical prostatectomy.status ...
Briganti A +23 more
core +1 more source
Is phosphodiesterase type 5 inhibitor use associated with condom breakage? [PDF]
, 2009 This is an open access article - Copyright © 2009 by the BMJ Publishing Group Ltd. All rights reserved.We tested the hypothesis that phosphodiesterase type 5 inhibitor (PDE5i) use would be associated with increased likelihood of condom breakage using an
Graham, C. A. +7 more
core +1 more source
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Journal of Microscopy and Ultrastructure, 2020 COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension;
Al-Kuraishy, Hayder M. +5 more
openaire +3 more sources
Why humans need type 5 phosphodiesterase inhibitors [PDF]
International Journal of Andrology, 2005 SummaryErectile dysfunction (ED) is a widespread medical condition affecting millions of males at any age and requiring medical treatment. ED may simply reflect a limit of human physiology, yet ED equates to genetic death and the high prevalence of ED is a clear evolutionary paradox.
CELLERINO, Alessandro, JANNINI E. A.
openaire +3 more sources
A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy [PDF]
, 2015 A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme,
Suardi N +6 more
core +3 more sources
Effects of the phosphodiesterase type-5 inhibitor tadalafil on nociception, morphine analgesia and tolerance in rats [PDF]
, 2018 Aim: Tadalafil is a potent, selective and reversible inhibitor of phosphodiesterase type 5 (PDE5) enzyme breakdowning cyclic guanosine monophosphate (cGMP).
Yasar Tastemur +9 more
core +2 more sources
Journal of Analytical Science and Technology, 2020 Avanafil (AV) is the phosphodiesterase (PDE) type 5 inhibitor drug used in erectile dysfunction, having pyrrolidine, pyrimidine, carboxamide, and chlorine as functional groups which can easily break by environmental changes and cause toxicity. Henceforth,
Mital Patel, Charmy Kothari
doaj +1 more source
The blue pill (sildenafil) and its descendants: an overview
Current Issues in Pharmacy and Medical Sciences, 2017 An increasing number of men around the world suffer from erectile dysfunction (ED). Indeed, according to the sexuality study conducted by Professor Izdebski, 1 out of 10 men in Poland suffers from ED.
Krzanowski Tomasz +3 more
doaj +1 more source
Indian Journal of Ophthalmology. Case Reports, 2022 Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common acute unilateral optic neuropathy in adults over the age of 50. Nocturnal hypotension has been hypothesized as the potential cause of NAION.
Samuel A Minaker, Arun N E Sundaram
doaj +1 more source
Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations. [PDF]
Patient Prefer Adherence, 2016 Lulu K Lee,1 Amir Goren,1 Natalie N Boytsov,2 Craig F Donatucci,2 Kevin T McVary3 1Health Outcomes Practice, Kantar Health, New York, NY, 2US Real World Outcomes Research, Eli Lily & Company, Indianapolis, IN, 3Division of Urology, Southern Illinois
Lee LK +4 more
europepmc +2 more sources